Steg PG, Bhatt DL, Simon T, et al. - Via a randomized, double-blind trial involving 19,220 patients, researchers determined whether adding ticagrelor to aspirin enhanced outcomes in patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke. In the ticagrelor and placebo groups, the incidence of an exploratory composite outcome of irreversible harm (death from any cause, myocardial infarction, stroke, fatal bleeding, or intracranial hemorrhage) was comparable. A lower incidence of ischemic cardiovascular events—but a greater incidence of major bleeding—was noted in those who received ticagrelor plus aspirin vs those who received placebo plus aspirin.